Approved by the fda, telaprevir and boceprevir usher in a new era of treatment by Larry Buhl The first breakthrough treatments for liver disease to be approved in twenty years are about to hit the market, giving new hope for the most difficult-to-treat patients with the hepatitis C virus (HCV). In May the FDA approved boceprevir, to be marketed as Victrelis by Merck & Co., and telaprevir, to be sold in North America by Vertex Pharmaceuticals under the name Incivek. Both drugs are targeted at [...]

A second hepatitis C antiviral—boceprevir—moves closer to approval